NCT06882174
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06882174
Title This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer (TIME-NSCLC)
Acronym TIME-NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AHS Cancer Control Alberta
Indications
Therapies
Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.